Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160467 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL6158921 | 0.70 | CA2 (0.36) | CDA | |
| SCHEMBL6159543 | 0.69 | PPIA (0.34) | — | |
| SCHEMBL6946153 | 0.69 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL5888096 | 0.67 | OPRM1 (0.33) | — | |
| SCHEMBL4827222 | 0.67 | SMN1; SMN2 (0.40) | CDASMN1; SMN2 | |
| SCHEMBL6698499 | 0.65 | KDM4E (0.31) | — | |
| SCHEMBL16771540 | 0.65 | EHMT2 (0.38) | EHMT2 | |
| SCHEMBL7976916 | 0.62 | — | — | |
| SCHEMBL6160461 | 0.61 | SMN1; SMN2 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423048-B2 | Compounds for treating fundic disaccomodation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7358239-B2 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-15 | — | — | US | disclosed |
| US-7081453-B2 | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | VAN EMELEN KRISTOF | 2006-06-29 | — | — | US | disclosed |
| EP-1296987-B1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050159406-A1 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | DE BRUYN MARCEL F L (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6900222-B1 | Pyrrolidinyl, piperdinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-31 | — | — | US | disclosed |
| EP-1187831-B1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | JANSSEN-CILAG S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
| EP-1296987-A1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1187831-A1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001098306-A1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000075137-A1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159406-A1 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | HRH2, CBR1, CBR3 | CDA 4753/4885EHMT2 2881/4885SMN1; SMN2 2742/4885 |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | CNR2, CNR1, CBR1 | CDA 3162/4885EHMT2 3429/4885SMN1; SMN2 2094/4885 |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | ALK, ADORA1, CHRM2 | CDA 3826/4885EHMT2 3009/4885SMN1; SMN2 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.